Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from ...

Lenvatinib, a well-established first-line treatment for advanced hepatocellular carcinoma, demonstrates the ability to reprogram the immunosuppressive tumour microenvironment into an immune ...

Dana Walker, vice president, Opdivo global programme lead, BMS, said: “HCC is the predominant type of liver cancer globally, including in the EU, and when diagnosed at the advanced or unresectable ...

Risk of proteinuria with atezolizumab plus bevacizumab versus lenvatinib in first-line systemic treatment for hepatocellular carcinoma. End-of-life (EOL) outcomes and healthcare utilization for ...

Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: Extended follow-up of a randomized controlled trial and post-treatment immune cell profiling. Nivolumab (NIVO) plus ...

Among patients with unresectable hepatocellular carcinoma (uHCC), the combination of Opdivo ... Yervoy showed a significant improvement in median OS compared with Lenvima (lenvatinib) or Nexavar ...

In LEAP-012, median PFS increased from 10 months with TACE to 14.6 months with the addition of lenvatinib (Lenvima ... treatment of unresectable hepatocellular carcinoma: A multicenter, open ...